Open access
Open access
Powered by Google Translator Translator

All Posts

M-A | Medial–lateral versus lateral-only pinning fixation in children with displaced supracondylar humeral fractures

16 May, 2023 | 14:32h | UTC

Medial–lateral versus lateral-only pinning fixation in children with displaced supracondylar humeral fractures: a meta-analysis of randomized controlled trials – Journal of Orthopaedic Surgery and Research

 


RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases

16 May, 2023 | 14:30h | UTC

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study – JAMA Network Open

 

Commentary on Twitter

 


Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer

16 May, 2023 | 14:25h | UTC

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study – Journal of Clinical Oncology

Commentaries:

At 5-Year Follow-Up, Benefits of Pembrolizumab on Clinical Outcomes in Squamous NSCLC Maintained – ASCO Daily News

Addition of Pembrolizumab to Chemotherapy in First-Line Treatment of Metastatic Squamous NSCLC: 5-Year Update of KEYNOTE-407 – The ASCO Post

Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine

 


RCT | Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia

16 May, 2023 | 14:24h | UTC

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström’s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström’s Macroglobulinemia – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Addition of Bortezomib to First-Line Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia – The ASCO Post

 


RCT | Interrupted vs. continuous suture technique for biliary-enteric anastomosis

16 May, 2023 | 14:22h | UTC

Interrupted versus continuous suture technique for biliary-enteric anastomosis: randomized clinical trial – BJS Open

 

Commentary on Twitter

 


Practice Guidance | Differential diagnosis of suspected COPD exacerbations in the acute care setting

15 May, 2023 | 13:26h | UTC

Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice – American Journal of Respiratory and Critical Care Medicine

 

Commentary on Twitter

 


Canadian Task Force advises fragility fracture screening for women over 65, but not for men or younger women

15 May, 2023 | 13:23h | UTC

Recommendations on screening for primary prevention of fragility fractures – Canadian Medical Association Journal

Related USPSTF Statement: Screening Osteoporosis to Prevent Fractures

 


Guideline | Acute dizziness and vertigo in the emergency department

15 May, 2023 | 13:25h | UTC

Guidelines for reasonable and appropriate care in the emergency department 3 (GRACE-3): Acute dizziness and vertigo in the emergency department – Academic Emergency Medicine

News Release: New guideline for treatment of acute dizziness and vertigo in the emergency department – Society for Academic Emergency Medicine

 


RCT | Rivaroxaban doesn’t reduce thrombotic events, hospitalization, or death in outpatients with COVID-19

15 May, 2023 | 13:19h | UTC

Summary: The PREVENT-HD trial, a double-blind, placebo-controlled randomized study, was conducted to evaluate the effectiveness of prophylactic anticoagulation in reducing venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor. The trial took place between August 2020 and April 2022 across 14 US integrated healthcare delivery networks, with 1,284 patients enrolled and randomly assigned to receive either 10 mg of oral rivaroxaban or placebo daily for 35 days.

However, the study was terminated prematurely due to enrollment challenges and lower-than-expected event rates. The primary efficacy outcome, a composite of various hazardous events, occurred in 3.4% of the rivaroxaban group and 3.0% of the placebo group, with no significant difference between the two groups (hazard ratio, 1.16 [95% CI, 0.63–2.15]; P=0.63). No critical-site or fatal bleeding was observed, and only one patient in the rivaroxaban group experienced a major bleed.

In conclusion, rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis does not appear to reduce the composite end point of venous and arterial thrombotic events, hospitalization, and death. The study’s premature termination and lower-than-expected event rates may limit the generalizability of these findings.

Article: Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial – Circulation

 

Commentary on Twitter

 


RCT | Prophylactic antibiotics show no statistically significant survival improvement in severe alcohol-related hepatitis

15 May, 2023 | 13:21h | UTC

Summary: This multicenter, randomized, double-blind clinical trial aimed to determine the efficacy of amoxicillin-clavulanate combined with prednisolone compared to placebo combined with prednisolone on mortality in patients hospitalized with severe alcohol-related hepatitis. The study involved 284 patients from 25 centers in France and Belgium with biopsy-proven severe alcohol-related hepatitis, who were followed up for 180 days.

The primary outcome was all-cause mortality at 60 days, while secondary outcomes included mortality at 90 and 180 days, infection rates, hepatorenal syndrome, and changes in Model for End-stage Liver Disease (MELD) and Lille scores. The results showed no statistically significant difference in 60-day mortality between the two groups, with 17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group. However, infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group compared to the placebo group.

It is worth noting that the study may have been underpowered, as the absolute risk difference of 4% did not achieve statistical significance. In conclusion, the combination of amoxicillin-clavulanate and prednisolone did not show a statistically significant improvement in 2-month survival in patients hospitalized with severe alcohol-related hepatitis compared to prednisolone alone. These findings do not support the use of prophylactic antibiotics to improve survival in this patient population, but the potential underpowered nature of the study should be considered.

Article: Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Cognitive behavioral therapy proves effective for severe post-COVID-19 fatigue

15 May, 2023 | 13:16h | UTC

Efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19: results of a randomized controlled trial – Clinical Infectious Diseases

News Release: Cognitive behavioral therapy lessens post-viral fatigue after COVID-19 – Amsterdam UMC

 

Commentary on Twitter

 


Therapeutic plasma exchange: Core curriculum 2023

15 May, 2023 | 13:14h | UTC

Therapeutic Plasma Exchange: Core Curriculum 2023 – American Journal of Kidney Diseases

 

Commentary on Twitter

 


Review | Intensive care unit–acquired weakness in patients with acute kidney injury

15 May, 2023 | 13:12h | UTC

Intensive Care Unit–Acquired Weakness in Patients With Acute Kidney Injury: A Contemporary Review – American Journal of Kidney Diseases

 

Commentary on Twitter

 


RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events

15 May, 2023 | 13:10h | UTC

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Novel autotaxin inhibitor Ziritaxestat shows no benefit for idiopathic pulmonary fibrosis

15 May, 2023 | 13:08h | UTC

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials – JAMA (free for a limited period)

 


RCT | Statins do not prevent early cardiac dysfunction in anthracycline-treated cancer patients

15 May, 2023 | 13:07h | UTC

Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines – European Heart Journal – Cardiovascular Pharmacotherapy (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Review | Heart failure and liver disease: cardiohepatic interactions

15 May, 2023 | 13:06h | UTC

Heart Failure and Liver Disease: Cardiohepatic Interactions – JACC: Heart Failure

 


M-A | Postoperative clinical outcomes for kinematically, restricted kinematically, or mechanically aligned total knee arthroplasty

15 May, 2023 | 13:04h | UTC

Postoperative clinical outcomes for kinematically, restricted kinematically, or mechanically aligned total knee arthroplasty: a systematic review and network meta-analysis of randomized controlled trials – BMC Musculoskeletal Disorders

 


An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders

15 May, 2023 | 13:02h | UTC

An Update on the Role of Immunohistochemistry in the Evaluation of Pancreatic/Liver/Gastrointestinal Luminal Tract Disorders – Archives of Pathology & Laboratory Medicine

 


Brief Review | Coagulation support during perioperative bleeding management

15 May, 2023 | 13:01h | UTC

Coagulation support during perioperative bleeding management – Intensive Care Medicine

 

Commentary on Twitter

 


RCT | Neck–shoulder region training for chronic headache in women

15 May, 2023 | 12:59h | UTC

Neck–Shoulder Region Training for Chronic Headache in Women: A Randomized Controlled Trial – Clinical Rehabilitation

 

Commentary on Twitter

 


Review | Nonalcoholic fatty liver disease from a primary care perspective

15 May, 2023 | 12:57h | UTC

Nonalcoholic fatty liver disease from a primary care perspective – Diabetes, Obesity and Metabolism

 


Review | Awake prone positioning in acute hypoxemic respiratory failure

15 May, 2023 | 12:56h | UTC

Awake prone positioning in acute hypoxaemic respiratory failure – European Respiratory Review

 


RCT | Transvenous occlusion of incompetent pelvic veins to treat chronic pelvic pain in women

15 May, 2023 | 12:54h | UTC

Transvenous occlusion of incompetent pelvic veins to treat chronic pelvic pain in women: A randomised controlled trial – BJOG

 


M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients

15 May, 2023 | 12:52h | UTC

Additional effects of exercise to hypocaloric diet on body weight, body composition, glycaemic control and cardio-respiratory fitness in adults with overweight or obesity and type 2 diabetes: A systematic review and meta-analysis – Diabetic Medicine

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.